PhRMA picks Pfizer CEO Kindler to chair; E.U. regulators advocate new Tarceva use;

  @FiercePharma: Why do Americans pay more for their meds? Article | Follow @FiercePharma

> Pfizer chief Jeffrey Kindler has been elected chairman of PhRMA, succeeding David Brennan, AstraZeneca's CEO. Release

> European drugs regulators have recommended that cancer drug Tarceva from OSI Pharmaceuticals and Roche be marketed for first-line maintenance of patients with locally advanced or metastatic non-small-cell lung cancer. Release

> Valeant Pharmaceuticals says it will buy a Brazilian generic and OTC drugmaker for about $28 million to expand its generics and dermatology portfolio. Release

> Reckitt Benckiser says it is buying back the sales and marketing rights to the buprenorphine-containing products Suboxone, Subutex and Temgesic from Merck for £100 million. Release

> Drug researcher Theravance said it expects to raise $86.3 million by selling additional shares to the public. Release

> An estimated 440,000 people had multidrug-resistant tuberculosis in 2008 and a third of them died as the new variant of the TB mycobacterium continues to spread. Report

Biotech News

   @FierceBiotech: Roche/Genentech try to develop companion diagnostic tests for all their experimental drugs. | Follow @FierceBiotech

   @JohnCFierce: I'm keeping my fingers crossed that this time the FDA is going to follow through on supporting innovation. It's been a long time coming. Report | Follow @JohnCFierce

> Roll Call has listed the highest-paid association lobbyists in 2009. Representatives from PhRMA and BIO took eight of the top 20 spots, with PhRMA's Mimi Kneuer coming in at number two with $830,559 in salary plus bonus. Item

> A.P. Pharma nausea drug hit with FDA rejection. Report

> OXiGENE filing includes going concern opinion. Story

> Roche looks to pipeline, new diseases for growth. Article

> France's Neovacs launches $27 million IPO. Report

> Drugmakers, non-profits to partner on TB drug development. Story

And Finally... A newspaper article has reawakened a controversy over whether provincial authorities in China improperly stored vaccines, rendering them ineffective, and then let them be administered to children. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.